Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 1.00 |
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TOP2A | P11388 | 1/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-(4-Fluorophenyl)Cinnamamide SCHEMBL9989034 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL11590995 | 0.91 | EGFR (0.92) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL4205896 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL2682029 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL3667414 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL707945 | 0.85 | EGFR (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL707946 | 0.85 | EGFR (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL9988799 | 0.85 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL18993398 | 0.85 | EGFR (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL262818 | 0.85 | MMP1 (0.86) | MMP1MMP2MMP9EGFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-106536518-B | Anthelmintic compounds | 勃林格殷格翰动物保健美国公司 | 2020-05-12 | — | — | CN | disclosed |
| US-10463661-B2 | Anthelmintic compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10463661-B2 | Anthelmintic compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180338972-A1 | ANTHELMINTIC COMPOUNDS | MERIAL INC. (US) | 2018-11-29 | — | — | US | disclosed |
| CN-108250128-A | Compound as potassium channel modulating agents | 江苏先声药业有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
| US-10463661-B2 | Anthelmintic compounds | HRH4, QTRT1, Q6ZSR9 | MMP1 1825/4885MMP2 1724/4885MMP9 1626/4885 |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | CYP3A5, ABCC5, CXXC5 | MMP1 1150/4885MMP2 1332/4885MMP9 1194/4885 |
| US-20180338972-A1 | ANTHELMINTIC COMPOUNDS | HRH4, QTRT1, Q6ZSR9 | MMP1 1825/4885MMP2 1724/4885MMP9 1626/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | MMP1 1150/4885MMP2 1332/4885MMP9 1194/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.